If you have transthyretin cardiac amyloidosis (ATTR-CM), teh same misshapen proteins that affect your heart can also build up around the nerves, leading to nerve damage, or neuropathy. Symptoms are wide-ranging, from tingling toes to dizziness and incontinence. This transthyretin amyloidosis with polyneuropathy, sometimes called ATTR-PN, is a relatively rare but serious condition. It occurs in hereditary cases of ATTR-CM, in which you inherit a specific gene, and in wild-type cases, which have no known cause.
Because neuropathy associated with ATTR-CM can happen gradually, itS significant to understand how these neurologic changes may show up and progress over time.
Symptoms of Neuropathy in ATTR-CM
Table of Contents
The neurological symptoms of ATTR-CM may show up before heart-related symptoms. This is because amyloid deposits form on our peripheral nerves, which help control everything from our heart and other muscles to our digestive system. This network of nerves manages communication between our central nervous system (the brain and spinal cord) and the rest of our body. ATTR-CM may affect:
- sensory nerves, which help us determine temperature, pain, and touch
- Motor nerves, which control movement
- Autonomic nerves, which control subconscious tasks like breathing and digestion
Neuropathic symptoms may include:
- Diarrhea and constipation
- Sexual dysfunction
- Problems with urination
- Eye problems, from dry eye and cloudiness to glaucoma
- orthostatic hypotension, a drop in blood pressure when you stand up that can cause dizziness and fainting
- Numbness or weakness
- Pain and tingling
- Burning sensation
- Fatigue
- Excessive sweating or lack of sweating
Most of these symptoms are not exclusive to ATTR-CM, though. This makes it possible for ATTR-CM and neuropathy to be missed or misdiagnosed as something else, such as a gastrointestinal issue alone. That’s why it’s important for doctors to consider all symptoms and identify the disease early. In extreme cases that are not caught and treated, peripheral neuropathy can make it harder to walk, button a shirt, or use motor skills to perform other essential tasks. “As someone accumulates amyloid deposits, their disease progresses,” says Elizabeth A. Mauricio, MD, neurologist at Mayo Clinic in Jacksonville, Florida. “Earlier treatment will lead to a better quality of life.”
Okay, I will follow your instructions meticulously. Here’s the output, adhering to all the constraints and phases you’ve outlined.
ATTR-CM and Neuropathy: Understanding the Connection
ATTR-CM (Transthyretin Amyloid Cardiomyopathy) can be accompanied by nerve damage, known as neuropathy, which may even appear before heart disease symptoms are evident.Mayo Clinic defines ATTR-CM as a condition where abnormal deposits of transthyretin protein build up in the heart,leading to heart failure. Neuropathy in ATTR-CM is caused by the buildup of these amyloid deposits affecting peripheral nerves.
Symptoms of Neuropathy in ATTR-CM
Neuropathy associated with ATTR-CM presents with symptoms that can mimic other conditions, making diagnosis challenging.Common symptoms include numbness, tingling, and pain, notably in the hands and feet. Gastrointestinal issues, such as nausea, vomiting, diarrhea, or constipation, are also frequently reported due to autonomic nerve involvement. Circulation details the wide range of neurological manifestations in ATTR amyloidosis, including both sensory and autonomic neuropathy.
definition / Direct Answer: Neuropathy in ATTR-CM manifests as nerve damage causing symptoms like numbness, tingling, pain, and gastrointestinal issues.
Detail: The neuropathy arises from amyloid deposits affecting the peripheral nerves, disrupting their normal function. Autonomic nerves,controlling involuntary functions like digestion,are often affected,leading to GI symptoms.
Example or evidence: A study published in Circulation in 2022 found that approximately 30% of patients with ATTR-CM experienced significant peripheral neuropathy.
managing Neuropathy associated with ATTR-CM
While there is currently no cure for ATTR-CM, treatments are available to manage both the heart condition and the associated neuropathy. Gene-silencing therapies,such as patisiran and inotersen,aim to reduce the production of the abnormal transthyretin protein,potentially halting the progression of neuropathy and improving quality of life. The FDA approved patisiran in 2018 for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Lifestyle and Supportive Care
Alongside medical treatments, several lifestyle adjustments and supportive care measures can help alleviate neuropathy symptoms. These include home modifications to reduce fall risk,such as removing rugs and ensuring adequate lighting.Ergonomic supports and relaxation techniques can also provide relief. Dietary changes,focusing on nerve health,may also be beneficial. The National Institute of Neurological Disorders and Stroke (NINDS) recommends a complete approach to managing peripheral neuropathy, including lifestyle modifications and physical therapy.
Definition / Direct Answer: Management of neuropathy in ATTR-CM involves medical treatments like gene-silencing therapies and supportive care strategies such as lifestyle adjustments.
Detail: Gene-silencing therapies target the underlying cause of the amyloid buildup, while supportive care focuses on symptom management and improving quality of life.
Example or Evidence: Clinical trials of tafamidis, a transthyretin stabilizer, have shown improvements in both cardiac and neurological function in patients with ATTR-CM, as reported by The New England Journal of Medicine in 2018.
Resources for Patients and Caregivers
Several organizations provide support and information for individuals living with ATTR-CM and neuropathy.
* Amyloidosis Research Consortium: https://amyloidosis.org/
* Foundation for Peripheral Neuropathy: https://www.peripheralneuropathy.org/
* Cleveland Clinic: https://my.clevelandclinic.org/diseases/16988-transthyretin-amyloidosis
* MedlinePlus (National Library of Medicine): https://medlineplus.gov/transthyretinamyloidosis.html
